期刊文献+

高龄患者输注西妥昔单抗注射液的观察与护理 被引量:1

高龄患者输注西妥昔单抗注射液的观察与护理
下载PDF
导出
摘要 高龄患者头颈部鳞癌应用西妥昔单抗分子靶向治疗,国内尚属新的领域,为了更好的做好护理,避免副反应的发生,故在1例患者治疗护理中通过加强与患者沟通、熟悉不良反应、仔细观察、尽早发现并及时预防,取得了较好的疗效,同时患者有了较好的耐受性,值得在今后工作中参考。 Application of elderly patients with head and neck squamous cell carcinoma Cetuximab molecular targeted therapy is still a new field of domestic.To do better nursing care and to avoid the occurrence of side effects, a case treatment and care of patients in our departments through enhanced communication with patients. Familiar with the adverse reactions, careful observation, early detection and timely prevention and achieved good effect,while patients with good tolerance, it is in reference to future work.
出处 《当代医学》 2010年第31期132-133,共2页 Contemporary Medicine
关键词 分子靶向治疗 西妥昔单抗 头颈部鳞癌 molecular targeted therapy Cetuximab head and neck squamous cell carcinoma
  • 相关文献

参考文献1

二级参考文献16

  • 1Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy [ J ]. Drugs, 2000,60(Suppl 1) :S15 - S23.
  • 2Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab [ J ] . Eur J Cancer, 2001,37 ( Suppl 4) : S16 - S22.
  • 3Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology(1MC-C225) [J].Curr Opin Oncol,2001,13(6) : 506 - 513.
  • 4Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy [ J ]. Expert Opin Investig Drugs, 2002, 11 (6) : 755 -768.
  • 5Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11)against human colorectal tumor xenografts [ J ]. Clin Cancer Res, 2002,8 ( 5 ) : 994 -1003.
  • 6Bianco C, Bianco R,Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide [ J ]. Clin Cancer Res,2000,6( 11 ) :4343 - 4350.
  • 7Folprecht G, Lutz MP, Schoeffski P, et al. Pharmacokinetic ( PK )evaluation of cetuximab in combination with weekly irinotecan( CPT-11 )and 24h infusional 5-FU/folinic acid(FA)as first line treatment in patients(pts) with epidermal growth factor receptor ( EGFR)-positive metastatic colorectal cancer(MCRC) [J]. Proc Am Soc Clin Oncol ,2003,22 (2) : 222.
  • 8Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and incombination with cisplatin [ J ]. J Clin Oncol , 2000,18 ( 4 ) : 904 -914.
  • 9Raoul JL, Van Laethem JL, Mitry E, et al. Phase Ⅱ study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid(FA) in patients(pts) with metastatic,epidermal growth factor receptor(EGFR)-expressing colorectal cancer(CRC)[J]. Eur J Cancer, 2003,1 ( Suppl 5) : S89.
  • 10Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225)plus weekly irinotecan (CPT-11), fluorouracil and leucovorin in colorectal cancer that expresses the epidermal growth factor receptor[abstract no.536][A].38^th Annual Meeting of the American Society of clinical Oncology[ C ], Orlando, 2002.

共引文献19

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部